menu
    • menu
    [{"orgOrder":0,"company":"Tubulis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"TUB-030","moa":"5T4 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tubulis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tubulis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tubulis \/ Undisclosed"},{"orgOrder":0,"company":"Tubulis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"TUB-030","moa":"5T4 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tubulis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tubulis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tubulis \/ Undisclosed"},{"orgOrder":0,"company":"Tubulis","sponsor":"WuXi Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Partnership","leadProduct":"TUB-010","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Tubulis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tubulis \/ Tubulis","highestDevelopmentStatusID":"4","companyTruncated":"Tubulis \/ Tubulis"},{"orgOrder":0,"company":"Tubulis","sponsor":"Biomedpartners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Series A Financing","leadProduct":"TUB-010","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Tubulis","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Tubulis \/ Biomedpartners","highestDevelopmentStatusID":"4","companyTruncated":"Tubulis \/ Biomedpartners"},{"orgOrder":0,"company":"Tubulis","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Series B Financing","leadProduct":"TUB-040","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tubulis","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"Injection","sponsorNew":"Tubulis \/ EQT Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Tubulis \/ EQT Life Sciences"},{"orgOrder":0,"company":"Tubulis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TUB-040","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tubulis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tubulis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tubulis \/ Undisclosed"},{"orgOrder":0,"company":"Tubulis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TUB-040","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tubulis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tubulis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tubulis \/ Undisclosed"},{"orgOrder":0,"company":"Tubulis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TUB-040","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tubulis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tubulis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tubulis \/ Undisclosed"},{"orgOrder":0,"company":"Tubulis","sponsor":"Andera Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Tubulis","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Tubulis \/ Andera Partners","highestDevelopmentStatusID":"6","companyTruncated":"Tubulis \/ Andera Partners"},{"orgOrder":0,"company":"Tubulis","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Tubulis","amount2":0.44,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.44,"dosageForm":"Undisclosed","sponsorNew":"Tubulis \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Tubulis \/ Gilead Sciences"},{"orgOrder":0,"company":"Tubulis","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Tubulis","amount2":1.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.02,"dosageForm":"Undisclosed","sponsorNew":"Tubulis \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Tubulis \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Tubulis","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Tubulis","amount2":1.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.02,"dosageForm":"Undisclosed","sponsorNew":"Tubulis \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Tubulis \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Tubulis","sponsor":"Biocytogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Tubulis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tubulis \/ Tubulis","highestDevelopmentStatusID":"4","companyTruncated":"Tubulis \/ Tubulis"}]

    Find Clinical Drug Pipeline Developments & Deals by Tubulis

    Menu

    Tubulis

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tubulis

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Tubulis

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Biocytogen

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Biocytogen Announces Tubulis Has Signed License Agreement for Single Antibody

                            Details : Tubulis has exercised an exclusive license for the global development and commercialization of a fully human antibody developed by Biocytogen.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            September 15, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Biocytogen

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tubulis

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Tubulis

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $1,022.7 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Tubulis-BMS Tubutecan ADC Enters Clinic Marking Strategic Milestone Achievement

                            Details : BMS will gain exclusive rights to access Tubulis’ Tubutecan payloads in combination with P5 conjugation platform for the development of ADCs to treat solid tumors.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $22.7 million

                            May 20, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $1,022.7 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tubulis

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Tubulis

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TUB-030

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TUB-030 First Patient Dosed in Solid Tumor ADC Phase I/IIa Trial

                            Details : TUB-030 is a next-generation, 5T4 modulator antibody-drug conjugate, which is being evaluated for the treatment of patients with advanced solid tumors.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            January 30, 2025

                            Lead Product(s) : TUB-030

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Tubulis

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Tubulis

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Gilead Sciences

                            Deal Size : $435.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Gilead Taps German biotech Tubulis for Solid Tumor ADC Development Deal Worth up to $465M

                            Details : The agreement aims to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target using Tubulis’ proprietary Tubutecan and Alco5 platforms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $20.0 million

                            December 03, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Gilead Sciences

                            Deal Size : $435.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Tubulis

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Tubulis

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TUB-030

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

                            Details : TUB-030 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            October 24, 2024

                            Lead Product(s) : TUB-030

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Tubulis

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Tubulis

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TUB-040

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tubulis Receives FDA Fast Track for TUB-040 in Platinum-resistant Ovarian Cancer

                            Details : TUB-040, a novel Napi2b-targeting ADC-based product., which is being evaluated for the treatment of patients with Ovarian Cancer and Non-small Cell Lung Cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 27, 2024

                            Lead Product(s) : TUB-040

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Tubulis

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Tubulis

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TUB-040

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tubulis Begins Phase I/IIa Trial of TUB-040 in Cancer

                            Details : TUB-040, a novel Napi2b-targeting ADC, is being evaluated in the Phase II clinical trial studies for the treatment of Ovarian Cancer and Non-small Cell Lung Cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 20, 2024

                            Lead Product(s) : TUB-040

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Tubulis

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Tubulis

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TUB-040

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : EQT Life Sciences

                            Deal Size : $138.8 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Tubulis Rides Wave of ADC Interest to $138M Financing Round

                            Details : The financing aims to support Tubulis' ongoing clinical development of TUB-040, a novel Napi2b-targeting ADC-based product being evaluated in Phase II trials for ovarian cancer & NSCLC.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            March 14, 2024

                            Lead Product(s) : TUB-040

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : EQT Life Sciences

                            Deal Size : $138.8 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Tubulis

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Tubulis

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TUB-040

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenoc...

                            Details : TUB-040 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Ovarian Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 12, 2024

                            Lead Product(s) : TUB-040

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Tubulis

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Tubulis

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $1,022.7 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for th...

                            Details : Through the license agreement, Bristol Myers Squibb will gain exclusive rights to access Tubulis’ Tubutecan payloads in combination with Tubulis’ proprietary P5 conjugation platform for the development of a selected number of highly differentiated AD...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $22.7 million

                            April 19, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $1,022.7 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth